Omnicell offers a compelling combination of 33% analyst upside, a PEG of 0.05, and free cash flow conversion of 551% relative to net income alongside a Piotroski F-Score of 8/9, but momentum has slipped below the minimum threshold and the stock trades well above the options market's max pain level of $35.
Thesis pillars
- Exceptional Fcf Piotroski Quality→Stable
- Analyst Upside Peg Value↑Improving
- Earnings Beat Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
Omnicell, Inc. (OMCL) Stock Analysis
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $41.00, but acceptable to hold if already in. Reasons: Earnings in 4 days (event risk); Negative momentum.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an... Read more
Hold if already holding. Not a fresh buy at $41.00, but acceptable to hold if already in. Reasons: Earnings in 4 days (event risk); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 4d<=7d. Suitability: aggressive.
Recent developments
updated 2026-07-26Recent Developments — Omnicell, Inc.
Latest news
- NEWS Omnicell Appoints COO Nnamdi Njoku As President, Effective July 1 — benzinga Jul 1, 2026 neutral
- NEWS Keybanc Maintains Overweight on Omnicell, Raises Price Target to $70 — benzinga Apr 29, 2026 positive
- NEWS 12 Health Care Stocks Moving In Tuesday's Intraday Session — benzinga Apr 28, 2026 neutral
- NEWS Crude Oil Gains Over 3%; General Motors Earnings Top Views — benzinga Apr 28, 2026 neutral
- NEWS Omnicell Q1 2026 Earnings Call Transcript — benzinga Apr 28, 2026 neutral
Generated 2026-07-26T06:22:14Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-07-01Item 5.02LOWNnamdi Njoku was appointed President effective July 1, 2026, while retaining his COO role. CEO Randall Lipps stepped down from the President title but remains CEO and Chairman; no compensation changes.SEC filing →
- 2026-05-26Item 5.02LOWStockholders approved an amendment to the 2009 Equity Incentive Plan at the May 19, 2026 Annual Meeting, adding 1,600,000 shares available for issuance. Routine plan amendment, not an executive departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $41.00, but acceptable to hold if already in. Reasons: Earnings in 4 days (event risk); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $53.32 (+30.0%), stop $38.13 (−7.5%), A.R:R 3.3:1. Score 5.6/10, moderate confidence.
Take-profit target: $53.32 (+30.0% upside). Target $53.32 (+30.0%), stop $38.13 (−7.5%), A.R:R 3.3:1. Stop-loss: $38.13.
Earnings in 4 days (event risk); Negative momentum.
Omnicell, Inc. trades at a P/E of 91.1 (forward 18.7). TrendMatrix value score: 6.5/10. Verdict: Hold.
14 analysts cover OMCL with a consensus score of 4.1/5. Average price target: $61.
What does Omnicell, Inc. do?Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and...
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.